{
    "nctId": "NCT05839288",
    "briefTitle": "Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients",
    "officialTitle": "Pyrotinib Plus Trastuzumab and Chemotherapy in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 161,
    "primaryOutcomeMeasure": "progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* woman, age \\> 18 years old\n* diagnosed with HER2 +Metastatic Breast Cancer\n* received pyrotinib plus trastuzumab and chemotherapy for at least one cycle, starting from 2018.07-2022.09\n* available medical history\n\nExclusion Criteria:\n\n* medical history was incomplete",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}